|
|
Volumn 1, Issue 10, 2002, Pages 751-752
|
|
Drug life-cycle technologies
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA1A INTERFERON;
CYCLOSPORIN A;
DESLORATADINE;
DILTIAZEM;
DRUG METABOLITE;
ESOMEPRAZOLE;
FLUOXETINE;
GENERIC DRUG;
INSULIN;
LEUPRORELIN;
LORATADINE;
METHYLPHENIDATE;
NANOPARTICLE;
NICOTINE;
OMEPRAZOLE;
PRISOLEC;
RAPAMYCIN;
SUMATRIPTAN SUCCINATE;
TRAMADOL;
UNCLASSIFIED DRUG;
ATTENTION DEFICIT DISORDER;
BIOLOGICAL THERAPY;
BIOTECHNOLOGY;
CHEMICAL MODIFICATION;
CHIRALITY;
COMMERCIAL PHENOMENA;
DRUG ADMINISTRATION ROUTE;
DRUG APPROVAL;
DRUG BIOAVAILABILITY;
DRUG COST;
DRUG DESIGN;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG PENETRATION;
DRUG PURITY;
DRUG SOLUBILITY;
DRUG STRUCTURE;
ESOPHAGITIS;
EXPIRATION DATE;
HYPERTENSION;
MIGRAINE;
NOTE;
PATENT;
PATIENT COMPLIANCE;
PRIORITY JOURNAL;
PRODUCTIVITY;
SUSTAINED RELEASE FORMULATION;
ARTICLE;
CHEMISTRY;
ECONOMICS;
HUMAN;
RESEARCH;
CHEMISTRY, PHARMACEUTICAL;
DRUG INDUSTRY;
HUMANS;
RESEARCH;
|
|
EID: 0036781949
PISSN: 14741776
EISSN: None
Source Type: Journal
DOI: 10.1038/nrd926 Document Type: Note |
|
Times cited : (15)
|
|
References (0)
|
